BCYC
Bicycle Therapeutics LtdNASDAQ
Healthcare • Biotechnology
Factor tilt: Micro-Cap Value
$3.61+3.74%
Close Nov 6, 2026
- Market cap
- $252M
- 1 month
- -5.2%
- 3 months
- -12.2%
- 1 year
- -41.5%
- 52-week range
- $3.38$7.52
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.46Quarter to Sep 30, 2026 · 8 analysts · revenue $12.2M · 0.0% in 30d
- Short interest
- 44.5% of float3.5M shares · settled Oct 15, 2026 · +4.5% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $61.21M
- Net income
- -$190.41M
- Free cash flow
- -$205.59M
- Book value
- $510.26M
- Total debt
- $13.68M
- P/E
- —
- Price / sales
- 4.1×
- Price / book
- 0.5×
- FCF yield
- -81.6%
- Net margin
- -311.1%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
Read more
The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
- Website
- bicycletherapeutics.com
- Headquarters
- Cambridge, United Kingdom
- Employees
- 288
- Listed
- May 23, 2019
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 31, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Jul 30, 2026 | $629.0K | -78.5% | 100.0% | -$54.6M | -$50.3M |
| Mar 2026filed Apr 30, 2026 | $887.0K | -91.1% | 100.0% | -$65.6M | -$60.8M |
| Dec 2025filed Mar 17, 2026 | $48.0M | +1,193.3% | — | -$24.7M | -$20.2M |
| Sep 2025filed Oct 30, 2025 | $11.7M | +338.5% | 100.0% | -$65.6M | -$59.1M |
| Jun 2025filed Aug 8, 2025 | $2.9M | -68.8% | -2,332.5% | -$86.6M | -$79.0M |
| Mar 2025filed May 1, 2025 | $10.0M | -48.9% | -474.0% | -$70.2M | -$60.8M |
| Dec 2024filed Feb 25, 2025 | $3.7M | -30.4% | -1,412.2% | -$67.7M | -$51.9M |
| Sep 2024filed Oct 31, 2024 | $2.7M | -50.0% | -1,605.8% | -$63.8M | -$50.8M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 17, 2026 | $72.6M | +105.8% | — | -$247.7M | -$219.0M |
| Dec 2024filed Feb 25, 2025 | $35.3M | +30.8% | -390.3% | -$209.9M | -$169.0M |
| Dec 2023filed Feb 20, 2024 | $27.0M | +86.5% | -480.1% | -$189.9M | -$180.7M |
| Dec 2022filed Feb 28, 2023 | $14.5M | +23.6% | — | -$116.7M | -$112.7M |
| Dec 2021filed Mar 1, 2022 | $11.7M | +12.6% | — | -$65.6M | -$66.8M |
| Dec 2020filed Mar 11, 2021 | $10.4M | -24.7% | -219.0% | -$52.0M | -$51.0M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched BCYC. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
3,453,064 shares short
+150,176 shares (+4.5%) vs Sep 30, 2026
44.5% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
3,302,888 shares short
-28,903 shares (-0.9%) vs Sep 15, 2026
42.5% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
3,331,791 shares short
+50,392 shares (+1.5%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
3,281,399 shares short
+56,946 shares (+1.8%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
3,224,453 shares short
+240,564 shares (+8.1%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
2,983,889 shares short
+970 shares (0%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind BCYC’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if BCYC is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
32 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 31 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
104 filers reported a long position in BCYC for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
76.7%
of the 37.3M shares 13-F filers reported
Moves vs Q1 2026
3 added1 trimmed
6 unchanged
Net shares held
+4.8%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | $46.2M · 10.9M shares | 10.9M | Unchanged |
| 2 | FCPM III SERVICES B.V. | $14.7M · 3.5M shares | 3.5M | Unchanged |
| 3 | ARMISTICE CAPITAL, LLC | $14.4M · 3.4M shares | 3.4M | Unchanged |
| 4 | Long Focus Capital Management, LLC | $14M · 3.3M shares | 3.3M | Unchanged |
| 5 | ACADIAN ASSET MANAGEMENT LLC | $8.3M · 2M shares | 2M | Unchanged |
| 6 | RENAISSANCE TECHNOLOGIES LLC | $6.5M · 1.5M shares | 1.5M | +56.6% |
| 7 | GSK plc | $6.5M · 1.5M shares | 1.5M | Unchanged |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/ | $3.8M · 902.2K shares | 902.2K | -12.3% |
| 9 | MARSHALL WACE, LLP | $3.4M · 797.9K shares | 797.9K | +111.5% |
| 10 | Qube Research & Technologies Ltd | $3.3M · 775.6K shares | 775.6K | +151.3% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of BCYC file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Aug 14, 2026 | ARMISTICE CAPITAL, LLC13G · passive · amended | 6.72% |
| May 15, 2026 | Long Focus Capital Management, LLC13G · passive | 6.6% |
| May 4, 2026 | Invus Global Management LLC13G · passive · amended | 3.1%under 5% |
Get the Full Analysis for BCYC
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.